Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Fahad Almugbel"'
Autor:
Shabbir M.H. Alibhai, Martine Puts, Fahad Almugbel, Allison Loucks, A. Berger, Rana Jin, Narhari Timilshina, Naser AlQurini, Lindy Romanovsky
Publikováno v:
Journal of Geriatric Oncology. 12:786-792
The Vulnerable Elders Survey (VES-13) is commonly used to identify older patients who may benefit from Comprehensive Geriatric Assessment (CGA) prior to cancer treatment. The optimal cut point of the VES-13 to identify those whose final oncologic tre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe22971a77ec3bd6a7ae870ca77d35f9
https://doi.org/10.1016/j.jgo.2020.12.002
https://doi.org/10.1016/j.jgo.2020.12.002
Autor:
Fahad Almugbel, Michelle B. Nadler, David W. Cescon, Laith Al-Showbaki, Eitan Amir, Alexandra Desnoyers
Publikováno v:
Journal of Cancer
Background: Multiple anti-PD-1/PD-L1 antibodies have been approved, and in some diseases, there is a choice of more than one. Comparative efficacy, safety and tolerability are unknown. Methods: Randomized trials (RCTs) supporting the registration of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a5a9a5571e348cfa9235ddd28b01d88
https://pubmed.ncbi.nlm.nih.gov/34093837
https://pubmed.ncbi.nlm.nih.gov/34093837
Publikováno v:
Journal of Clinical Oncology. 39:e18616-e18616
e18616 Background: PD-1/PD-L1 targeting monoclonal antibodies (mAbs) improve outcomes in multiple cancer types. Multiple mAbs are in clinical development, and many randomized control trials (RCTs) have been completed or are in progress. These RCTs co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::48dca97f2ec806474b956e4fcb604a7d
https://doi.org/10.1200/jco.2021.39.15_suppl.e18616
https://doi.org/10.1200/jco.2021.39.15_suppl.e18616
Autor:
Husam Alqaisi, Raymond Woo-Jun Jang, Marta Honório, Fahad Almugbel, Shabbir M.H. Alibhai, Elena Elimova, Laith Al-Showbaki, Osvaldo Espin-Garcia, Chihiro Suzuki
Publikováno v:
Journal of Clinical Oncology. 39:193-193
193 Background: Although age is a non-modifiable risk factor for most cancers, alone it is not very helpful in deciding on the best treatment for patients. Insufficient data exist in the oldest old ( > 75 years) compared to young-old (65-75 years) an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ec4a1feeacbcc1b65f40b3109aced04a
https://doi.org/10.1200/jco.2021.39.3_suppl.193
https://doi.org/10.1200/jco.2021.39.3_suppl.193
Autor:
Narhari Timilshina, Rana Jin, Fahad Almugbel, Naser AlQurini, Arielle Berger, Shabbir M.H. Alibhai, Lindy Romanovsky, Allison Loucks, Martine Puts
Publikováno v:
Journal of Clinical Oncology. 38:e24020-e24020
e24020 Background: The Vulnerable Elders Survey (VES-13) is one of several tools that can identify older patients who are vulnerable (if the score is ≥ 3 out of 10) and more likely to benefit from Comprehensive Geriatric Assessment (CGA) prior to c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::27577809e77ed82e835bf5e21c0b3b79
https://doi.org/10.1200/jco.2020.38.15_suppl.e24020
https://doi.org/10.1200/jco.2020.38.15_suppl.e24020
Autor:
David W. Cescon, Alexandra Desnoyers, Laith Al-Showbaki, Michelle B. Nadler, Eitan Amir, Fahad Almugbel
Publikováno v:
Journal of Clinical Oncology. 38:e15151-e15151
e15151 Background: Multiple ICIs have been approved, and in some diseases there is a choice of more than one ICI. The comparative safety, efficacy, and tolerability are not known. Here we report on a network meta-analysis comparing different ICIs tar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::46685b8553304cff18d05f2bb73a4e32
https://doi.org/10.1200/jco.2020.38.15_suppl.e15151
https://doi.org/10.1200/jco.2020.38.15_suppl.e15151
Autor:
Ramy Saleh, Alexandra Desnoyers, Rouhi Fazelzad, Michelle B. Nadler, Jordan L Scott, Eitan Amir, Fahad Almugbel
Publikováno v:
Journal of Clinical Oncology. 38:e19121-e19121
e19121 Background: The programmed cell death 1 (PD-1)/programmed cell death 1 ligand 1 (PD-L1) pathway plays a crucial role in cancer immuno-surveillance and is the target of approved immunotherapeutic drugs. Available data suggest a variable prognos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cafddf1a194c056f5cca47c1d379c0b4
https://doi.org/10.1200/jco.2020.38.15_suppl.e19121
https://doi.org/10.1200/jco.2020.38.15_suppl.e19121
Autor:
Michelle B. Nadler, Ramy Saleh, Fahad Almugbel, Laith Al-Showbaki, Eitan Amir, Alexandra Desnoyers
Publikováno v:
Journal of Clinical Oncology. 38:e13080-e13080
e13080 Background: Capecitabine is an effective oral chemotherapy that is widely used in a number of solid cancers both as monotherapy or in combination with other anti-cancer drugs. It has been suggested that mean corpuscular volume (MCV) is associa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::877540b093e362414693e6c5252b4666
https://doi.org/10.1200/jco.2020.38.15_suppl.e13080
https://doi.org/10.1200/jco.2020.38.15_suppl.e13080